Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(cobimetinib)
253 results
  • Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. [Journal Article]
    Value Health 2020; 23(1):52-60Gorry C, McCullagh L, Barry M
  • CONCLUSIONS: Despite differences in model structures and assumptions, the conclusions of most included studies were consistent. Health technology assessment has a key role in maximizing value from high-cost innovative treatments. Consideration should be given to divestment from BRAF/MEK inhibitors and ipilimumab in favor of reimbursement of PD-1 inhibitors.
  • New Promise and Opportunities for Allosteric Kinase Inhibitors. [Journal Article]
    Angew Chem Int Ed Engl 2019Lu X, Smaill JB, Ding K
  • Drugs that function through allosteric inhibition of kinase signaling represent a promising approach for the targeted discovery of therapeutics with exceptional selectivity. The approval of cabozantinib, cobimetinib and binimetinib, three allosteric kinase inhibitors, and the experience derived from others under clinical evaluation has validated the concept of allosteric kinase inhibition. Signif…
  • A novel side effect of mitogen-activated protein kinase inhibitor cobimetinib: Acute corneal decompensation. [Case Reports]
    Indian J Ophthalmol 2019; 67(12):2073-2075Asfuroglu M, Asfuroğlu Y
  • A 38-year-old man with a diagnosis of BRAF-mutated metastatic melanoma was referred to our clinic. He had been under treatment with 60-mg oral cobimetinib daily for 21 days/7 day off in combination with 960 mg vemurafenib twice daily. The patient had symptoms of blurred vision and photophobia in his right eye. A slit-lamp examination revealed bilateral central corneal stromal opacity and epitheli…
New Search Next